Skip to Content

Signifor Approval History

  • FDA approved: Yes (First approved December 14th, 2012)
  • Brand name: Signifor
  • Generic name: pasireotide
  • Dosage form: Injection
  • Company: Novartis Pharmaceuticals Corporation
  • Treatment for: Cushing's Syndrome

Signifor (pasireotide) is a multireceptor targeting somatostatin analog for the treatment of patients with Cushing's disease.

Development History and FDA Approval Process for Signifor

Dec 14, 2012Approval FDA Approves Signifor, a New Orphan Drug for Cushing’s Disease
Nov  7, 2012Novartis drug Signifor recommended by FDA advisory committee for approval to treat patients with Cushing's disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.